Centauri Therapeutics

Centauri Therapeutics receives Innovate UK Biomedical Catalyst Award

Tuesday, September 12, 2017

Centauri Therapeutics, a biotechnology company focused on the treatment of infectious diseases and cancer, has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst (BMC) program. Alongside backing from the company’s investors, this award from the U.K.’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias, using the company’s Alphamer technology.

[Read More]